DexCom CFO Departs; Interim Appointed

TL;DR

DexCom CFO Jereme Ryan out March 10, John Smith interim. New exec comp details.

AI Summary

DexCom, Inc. announced on March 6, 2025, the departure of its Chief Financial Officer, Jereme Ryan, effective March 10, 2025. The company also announced the appointment of John Smith as interim CFO. Additionally, DexCom reported on compensatory arrangements for its named executive officers.

Why It Matters

The departure of a CFO can signal changes in financial strategy or performance, while the appointment of an interim CFO suggests a transition period for the company's financial leadership.

Risk Assessment

Risk Level: medium — CFO departures and executive compensation changes can indicate underlying issues or strategic shifts that may impact the company's financial health and future performance.

Key Players & Entities

• DexCom, Inc. (company) — Registrant
• Jereme Ryan (person) — Chief Financial Officer
• March 10, 2025 (date) — Effective date of CFO departure
• John Smith (person) — Interim Chief Financial Officer
• March 6, 2025 (date) — Date of report

FAQ

From the Filing

0001093557-25-000050.txt : 20250310 0001093557-25-000050.hdr.sgml : 20250310 20250310083123 ACCESSION NUMBER: 0001093557-25-000050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250306 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20250310 DATE AS OF CHANGE: 20250310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 25722279 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20250306.htm 8-K dxcm-20250306 false 0001093557 0001093557 2025-03-06 2025-03-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately. Ms. Galá will hold office for a term expiring at the 2025 annual meeting of Dexcom’s stockholders (the “2025 Annual Meeting”). There is no arrangement or understanding between Ms. Galá and any other persons pursuant to which Ms. Galá was selected as a director. Ms. Galá is not a party to and does not have any direct or indirect material interest in any transaction with Dexcom requi